Company Overview
PMGC Holdings Inc. operates as a biopharmaceutical entity dedicated to the development and acquisition of advanced aesthetic medicines and therapeutic products, with a specific strategic focus on obesity management. The company's primary innovation is EL-22, which represents a first-in-class engineered probiotic approach designed to address the critical issue of preserving muscle mass while treating obesity. This enterprise functions within the broader Healthcare sector, specifically categorized under the Biotechnology industry, positioning it as an early-stage innovator seeking to disrupt traditional metabolic health treatments. The company currently maintains a very small operational footprint with only two employees, and its total market capitalization stands at $904,239, while its trailing twelve-month revenue is $285,948. These valuation and revenue figures indicate that the company is a micro-cap entity with minimal historical sales, reflecting a stage of development where capital efficiency and product pipeline success are the primary drivers of future potential rather than established cash flow.
Financial Health
The company reported a trailing twelve-month revenue of $285,948, yet its net income for the same period was a significant loss of $-6,494,148, highlighting a severe disconnect between top-line activity and profitability. EBITDA further underscores this financial strain at $-5,812,148, suggesting that operating expenses and research costs far exceed current revenue generation capabilities. The free cash flow stands at $-3,585,391, indicating that the company is burning through its limited liquidity reserves to fund operations and product development without generating positive cash returns. Gross margin is listed at -82.0%, a negative figure that implies the cost of goods sold exceeds the revenue generated per unit, a common characteristic in early-stage biotechnology where manufacturing scale has not yet been achieved. Operating margin sits at -752.0% and profit margin at 0.0%, both metrics illustrating extreme operational inefficiency relative to current sales volume and a complete lack of net profit generation. On the balance sheet, the company holds $8.61M in cash against $4.41M in debt, resulting in a debt-to-equity ratio of 51.93, which suggests a highly leveraged position given the small equity base and negative earnings. Despite the high leverage, the current ratio is 1.79, indicating that the company theoretically possesses sufficient current assets to cover its short-term liabilities, though this liquidity is precarious given the ongoing cash burn. Return on Equity is -76.2% and Return on Assets is -28.0%, revealing that management is currently utilizing shareholder capital and assets to generate substantial losses rather than positive returns.
Valuation Assessment
Trailing P/E and forward P/E ratios are both listed as N/A due to the absence of net income, meaning traditional earnings-based valuation models cannot be applied to assess the company's expected earnings trajectory. The price-to-book ratio is 0.01, a figure that indicates the market values the company at a fraction of its book value, reflecting a significant discount often seen in speculative biotechnology stocks with unproven assets. Price-to-sales stands at 3.16, which suggests the market is willing to pay a premium relative to sales, while the EV/EBITDA multiple of 0.71 indicates a valuation based on enterprise value that is heavily influenced by the company's debt structure and lack of earnings. The 52-week high is $467.37 and the 52-week low is $1.62, creating a massive price range that suggests extreme volatility and a lack of consensus on the company's fair value. Although the specific current price is not listed in the provided data, the disparity between the high and low implies that the stock price sits within a highly unstable range relative to its historical extremes. The beta value is 1.13, which means the stock exhibits price volatility that is slightly higher than the broader market, making it more sensitive to market fluctuations than the average asset.
Growth & Income
Revenue growth year-over-year is -45.8%, while earnings growth is listed as N/A due to the lack of prior comparable earnings data, making a direct comparison of growth rates impossible. The negative revenue growth rate indicates a contraction in sales, which implies that the company is currently unable to expand its market presence or successfully commercialize its pipeline at a scale that drives top-line expansion. As a non-dividend payer with a dividend yield of N/A and a payout ratio of 0.0%, the company does not distribute income to shareholders and instead retains all capital for internal reinvestment into growth initiatives. Consequently, the overall growth and income profile is defined by significant revenue contraction and a complete absence of dividend income, characterizing the asset as a pure-play speculative opportunity reliant entirely on future product success rather than current profitability or shareholder returns.